TriGuard™HDH embolic deflection device for cerebral protection during transcatheter aortic valve replacement
| Autor: | Pierfrancesco Agostoni, F. Ramjankhan, Jeroen Hendrikse, Mariam Samim, Freek Nijhoff, Pieter A. Doevendans, Ricardo P.J. Budde, Pieter R. Stella, Bart van der Worp |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Aortic arch
medicine.medical_specialty Transcatheter aortic Intracranial Embolism business.industry medicine.medical_treatment General Medicine 030204 cardiovascular system & hematology medicine.disease Prosthesis Clinical trial 03 medical and health sciences 0302 clinical medicine Valve replacement Internal medicine Aortic valve stenosis medicine.artery medicine Cardiology Radiology Nuclear Medicine and imaging 030212 general & internal medicine Radiology Cardiology and Cardiovascular Medicine Symptomatic aortic stenosis business |
| Zdroj: | Catheterization and Cardiovascular Interventions. 89:470-477 |
| ISSN: | 1522-1946 |
| Popis: | Objectives: This study aims to evaluate the safety and performance of the new embolic deflection device TriGuard™HDH in patients undergoing TAVR. Background: Transcatheter aortic valve replacement (TAVR) is associated with a high incidence of new cerebral ischemic lesions. The use of an embolic protection device may reduce the frequency of TAVR-related embolic events. Methods: This prospective, single arm feasibility pilot study included 14 patients with severe symptomatic aortic stenosis scheduled for TAVR. Cerebral diffusion weighted magnetic resonance imaging (DWI) was planned in all patients one day before and at day 4 (±2) after the procedure. Major adverse cerebral and cardiac events (MACCEs) were recorded for all patients. Primary endpoints of this study were I) device performance success defined as coverage of the aortic arch takeoffs throughout the entire TAVR procedure and II) MACCE occurrence. Secondary endpoints included the number and the volume of new cerebral ischemic lesions on DWI. Results: Thirteen patients underwent transfemoral TAVR and one patient a transapical procedure. Edwards SAPIEN valve prosthesis was implanted in 8 (57%) patients and Medtronic CoreValve prosthesis in the remaining 6 (43%). Predefined performance success of the TriGuard™HDH device was achieved in 9 (64%) patients. The composite endpoint MACCE occurred in none of the patients. Post-procedural DWI was performed in 11 patients. Comparing the DWI of these patients to a historical control group showed no reduction in number [median 5.5 vs. 5.0, P=0.857], however there was a significant reduction in mean lesion volume per patient [median 13.8 vs. 25.1, P=0.049]. Conclusion: This study showed the feasibility and safety of using the TriGuard™HDH for cerebral protection during TAVR. This device did not decrease the number of post-procedural new cerebral DWI lesions, however its use showed decreased lesion volume as compared to unprotected TAVR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text